Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Brief: Nyxoah Q1 Net Loss Group Share Widens To EUR 6.8 Million

May 10 (Reuters) - Nyxoah SA  NYXH.BR :
    * REG-NYXOAH REPORTS FIRST QUARTER 2022 FINANCIAL AND
OPERATING
RESULTS
    * COMPLETED FIRST COMMERCIAL COMPLETE CONCENTRIC COLLAPSE
(CCC)
PATIENTS IN GERMANY
    * ACCELERATED MONTHLY PATIENT ENROLLMENT IN DREAM U.S. IDE
STUDY
AND CONTINUE TO EXPECT IMPLANTS TO BE COMPLETED IN Q2 OF 2022
    * TOTAL OPERATING LOSS FOR Q1 OF 2022 WAS EUR 7.3 MILLION
VERSUS
EUR 5.3 MILLION IN Q1 OF 2021
    * REVENUE WAS EUR 660,000 FOR Q1 ENDING MARCH 31, 2022,
COMPARED
TO EUR 185,000 FOR Q1 ENDING MARCH 31, 2021
    * AS OF MARCH 31, 2022, CASH AND FINANCIAL ASSETS TOTALED
EUR
127.8 MILLION ON MARCH 31, 2022, COMPARED TO EUR 135.5 MILLION
ON DECEMBER 31, 2021
    * EXPECTS MONTHLY CASH BURN TO INCREASE SLIGHTLY AS YEAR
PROGRESSES TO ACCOUNT FOR COMMENCEMENT OF ACCCESS IDE TRIAL IN
U.S., AND CURRENT CASH POSITION PROVIDES AMPLE LIQUIDITY TO GET
TO U.S. COMMERCIALIZATION IN 2024
    * ACCELERATED MONTHLY PATIENT ENROLLMENT IN DREAM U.S. IDE
STUDY
AND CONTINUE TO EXPECT IMPLANTS TO BE COMPLETED IN Q2 OF 2022
    * Q1 NET LOSS GROUP SHARE EUR 6.8 MILLION VERSUS LOSS EUR
5.7
MILLION YEAR AGO
    * WE ALSO CONTINUE OUR DIALOGUE WITH FDA REGARDING OUR IDE
SUBMISSION FOR OUR ACCCESS TRIAL FOR CCC PATIENTS IN U.S., AND
WE EXPECT TO IMPLANT OUR FIRST PATIENT BEFORE END OF THIS YEAR."
    * EXITED Q1 WITH 15 ACTIVE IMPLANT SITES IN GERMANY,
REPRESENTING
25% GROWTH OVER Q4 2021
    * IN GERMANY, EXPECTS TO ADD AN EXTRA 10 SITES BY END OF Q3
OF
2022
    * COST OF GOODS SOLD WAS EUR 289,000 FOR THREE MONTHS ENDING
MARCH
31, 2022, REPRESENTING A GROSS PROFIT OF EUR 371,000, OR GROSS
MARGIN OF 56.2%

Source text for Eikon:  ID:nGNEbgTSD9 
Further company coverage:  NYXH.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Nyxoah SA

See all news